NCT02800486View on ClinicalTrials.gov

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions
GlioblastomaAnaplastic AstrocytomaAnaplastic OligoastrocytomaGliomaBrain NeoplasmBrain CancerBrain TumorBrain Tumor, RecurrentBrain Neoplasm, Malignant
Interventions
DRUG

Intra-arterial Cetuximab

DRUG

Intra-arterial Mannitol

RADIATION

Hypofractionated re-irradiation

Trial Locations (1)

10075

RECRUITING

Lenox Hill Brain Tumor Center, New York

Sponsors

Lead Sponsor

Northwell Health
All Listed Sponsors
lead

Northwell Health

OTHER